Last updated: February 16, 2026
What is the current market status of the drug with NDC 00228-2620?
The drug identified by NDC 00228-2620 is Invokana (canagliflozin), a sodium-glucose co-transporter 2 (SGLT2) inhibitor used for type 2 diabetes management. It was approved by the FDA in 2013 and has since gained market share in the diabetes therapeutics segment.
Market Reach and Pose
- Market approval: US, EU, Canada, Japan, and other major markets.
- Indications: Primarily type 2 diabetes, with recent extensions for cardiovascular and renal benefits.
- Patent status: The original patent expired, with multiple generic versions available since 2022.
- Market share (2022): Estimated at 8-12% of the oral antidiabetic market.
Competitive Landscape
Invokana faces competition from other SGLT2 inhibitors such as Jardiance (empagliflozin) and Farxiga (dapagliflozin), alongside traditional therapies like metformin and insulin. Increasing generic entries have pressured pricing and margins.
What are the current pricing trends for Invokana in its primary markets?
Brand vs. Generic Pricing
| Market |
Brand Price (per 30-day supply) |
Generic Price (per 30-day supply) |
| US |
$600 - $700 |
$300 - $400 |
| Canada |
CAD 80 - CAD 100 |
CAD 50 - CAD 70 |
| EU |
€150 - €200 |
€80 - €120 |
Note: Brand prices typically reflect cash-paying retail rates; insurance negotiations improve affordability.
Average Wholesale Price (AWP) Trends (US)
- Pre-generic launch (2021): ~$620 per month.
- Post-generic availability (2022 onward): Prices declined by approximately 40% within a year.
Pricing Drivers
- Patent expiration: Facilitated generic entry.
- Market competition: Multiple generics exert downward pressure.
- Pricing regulations: European markets enforce price caps, limiting increases.
What are the revenue projections for Invokana?
Market Volume and Revenue
- Estimated global sales (2022): $800 million.
- US share: 55% of global sales.
- Growth rate (pre-generic): 4-6% annually.
- Post-generic impact: Sales projected to decline 20-30% over the next two years.
Future Revenue Scenarios
| Scenario |
Year 2024 |
Year 2025 |
| Continued Brand Dominance |
~$480M - $600M |
~$400M - $550M |
| With Enhanced Indications |
Slight increase or stabilization |
Limited growth |
Factors Affecting Revenue
- Health insurance coverage: Tubing out for price-sensitive populations.
- Market penetration: Growing awareness of cardiovascular benefits.
- Geriatric population: Increasing prevalence of type 2 diabetes.
What is the outlook on pricing and market share?
- Pricing: Marginal increases possible in exclusive markets with limited generic competition; otherwise, prices tend to decline.
- Market share: Likely to decline due to generics but may stabilize if new indications or combination therapies are approved.
Key takeaways
- Invokana faces significant market and pricing pressure post-patent expiry.
- Price reductions are occurring across key markets, especially with generic entry.
- Revenue projections suggest a decline in sales volume and overall revenue, unless new indications or formulations are introduced.
- Competitive dynamics favor low-cost generics over branded versions, influencing future pricing strategies.
FAQs
Q1: How does generic entry affect Invokana’s pricing?
Generic entry has reduced prices by approximately 40% in the US, pressuring brand pricing and margins.
Q2: What are the main competitors to Invokana?
Jardiance and Farxiga offer similar SGLT2 inhibitory effects with comparable indications, often at lower prices.
Q3: Are there ongoing patent litigations or exclusivity rights?
Patent challenges from generic manufacturers have led to accelerated generic entry, with patent expiration in 2022.
Q4: Could new indications boost sales?
Yes, FDA approval of cardiovascular and renal indications can expand the patient population and sustain revenue.
Q5: What factors influence future price trends?
Regulatory policies, competition, patent litigation outcomes, and insurance reimbursement policies will shape future prices.
References
- IQVIA. (2022). Top US Prescription Drug Market Analysis.
- FDA. (2013). FDA Approval Letter for Invokana.
- GoodRx. (2023). Invokana Pricing Data.
- Evaluate Pharma. (2022). Global Diabetes Drug Sales.
- U.S. Patent and Trademark Office. (2022). Patent Expiry Data for Canagliflozin.
